Pharmacogenomics and Star Allele Nomenclature

Fundamental Principles of Pharmacogenomics

• Definition of Pharmacogenomics: The study of how genetic variation among individuals affects their response to pharmaceutical drugs.
• Star Allele Nomenclature: A standardized system used to name genetic variants specifically within drug-metabolizing genes. The nomenclature follows a fixed format: $Gene*Number$. Examples of this format include $CYP2D6*4$ and $CYP2C19*2$.
• The Reference Allele: The $*1$ designation is usually reserved for the normal, or "wild-type," allele found in the population.

Functional Categories of Star Alleles

Genetic variations are categorized based on their impact on the gene's functional capacity:

• Normal Function: Designated by the $*1$ allele.
• Reduced Function: Characterized by a partial decrease in enzymatic activity. Specific examples include $CYP2D6*10$ and $CYP2C9*2$.
• No Function (Loss of Function): Characterized by a total lack of enzymatic activity. Specific examples include $CYP2D6*4$, $CYP2C19*2$, and $CYP2C19*3$.
• Increased Function (Gain of Function): Characterized by activity levels higher than the wild-type. A primary example is $CYP2C19*17$.

Metabolizer Phenotypes and Corresponding Genotypes

The combination of alleles (genotype) determines the patient's metabolizer phenotype:

• Normal Metabolizers: Typically possess the $*1/*1$ genotype.
• Intermediate Metabolizers: Typically possess a combination of a normal and a non-functional allele, such as $*1/*4$.
• Poor Metabolizers: Typically possess two non-functional alleles, such as $*4/*4$.
• Ultrarapid Metabolizers: Identified by the $*1xN$ genotype, which represents gene duplication rather than just a specific mutation.

Cardiovascular Pharmacogenomics Applications

Specific gene-drug interactions are critical in managing cardiovascular conditions:

• Clopidogrel and $CYP2C19$:
  • Mechanism: Clopidogrel is a prodrug that must be activated by the $CYP2C19$ enzyme.
  • Impact of Loss of Function: Carriers of the $*2$ or $*3$ alleles have reduced drug activation, which leads to an increased risk of thrombosis (blood clots).
  • Impact of Gain of Function: Carriers of the $*17$ allele experience increased drug activation, which raises the risk of bleeding complications.
• Warfarin and $CYP2C9$:
  • Mechanism: Warfarin is metabolized (cleared) by the $CYP2C9$ enzyme.
  • Impact of Allelic Variation: The $*2$ and $*3$ alleles cause reduced metabolism of the drug.
  • Clinical Consequences: Reduced metabolism leads to an increased risk of bleeding and necessitates lower maintenance doses of the medication.

Psychiatric Pharmacogenomics Applications

Genetic testing is frequently utilized for antidepressant and antipsychotic management:

• The Role of $CYP2D6$:
  • Drugs Affected: This enzyme metabolizes fluoxetine, paroxetine, venlafaxine, risperidone, and aripiprazole.
  • Poor Metabolizer Outcomes: Patients accumulate the drug in their system, leading to the development of adverse effects.
  • Ultrarapid Metabolizer Outcomes: Patients clear the drug too quickly, which may lead to treatment failure.
• The Role of $CYP2C19$:
  • Drugs Affected: This enzyme affects the levels of citalopram, escitalopram, and sertraline.
  • Impact of $*2$ Allele: This variant increases the levels of the drug in the bloodstream.
  • Impact of $*17$ Allele: This variant results in lowered levels of the drug in the bloodstream.

High-Yield Summary Points

• Allele Key: $*1$ = Normal; $*2$, $*3$, and $*4$ = Loss of function; $*17$ = Gain of function.
• Ultrarapid Metabolism: Often triggered by gene duplication, denoted as $*1xN$.
• Clinical Focus by Specialty:
  • Cardiovascular: Primarily involves the genes $CYP2C19$ and $CYP2C9$.
  • Psychiatry: Primarily involves the genes $CYP2D6$ and $CYP2C19$.